BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28791799)

  • 1. Reducing the Flexibility of Type II Dehydroquinase for Inhibition: A Fragment-Based Approach and Molecular Dynamics Study.
    Peón A; Robles A; Blanco B; Convertino M; Thompson P; Hawkins AR; Caflisch A; González-Bello C
    ChemMedChem; 2017 Sep; 12(18):1512-1524. PubMed ID: 28791799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the key factors that control the inhibition of type II dehydroquinase by (2R)-2-benzyl-3-dehydroquinic acids.
    Peón A; Otero JM; Tizón L; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Gago F; Castedo L; González-Bello C
    ChemMedChem; 2010 Oct; 5(10):1726-33. PubMed ID: 20815012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of new nanomolar competitive inhibitors of Helicobacter pylori type II dehydroquinase. Structural details of the role of the aromatic moieties with essential residues.
    Prazeres VF; Tizón L; Otero JM; Guardado-Calvo P; Llamas-Saiz AL; van Raaij MJ; Castedo L; Lamb H; Hawkins AR; González-Bello C
    J Med Chem; 2010 Jan; 53(1):191-200. PubMed ID: 19911771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic basis of the inhibition of type II dehydroquinase by (2S)- and (2R)-2-benzyl-3-dehydroquinic acids.
    Lence E; Tizón L; Otero JM; Peón A; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; González-Bello C
    ACS Chem Biol; 2013 Mar; 8(3):568-77. PubMed ID: 23198883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative binding energy COMBINE analysis for understanding the binding determinants of type II dehydroquinase inhibitors.
    Peón A; Coderch C; Gago F; González-Bello C
    ChemMedChem; 2013 May; 8(5):740-7. PubMed ID: 23450741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competitive inhibitors of Helicobacter pylori type II dehydroquinase: synthesis, biological evaluation, and NMR studies.
    Sánchez-Sixto C; Prazeres VF; Castedo L; Suh SW; Lamb H; Hawkins AR; Cañada FJ; Jiménez-Barbero J; González-Bello C
    ChemMedChem; 2008 May; 3(5):756-70. PubMed ID: 18200648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Shikimate Kinase and Type II Dehydroquinase for Antibiotic Discovery: Structure-Based Design and Simulation Studies.
    Gonzalez-Bello C
    Curr Top Med Chem; 2016; 16(9):960-77. PubMed ID: 26303426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and structural analysis of aromatic inhibitors of type II dehydroquinase from Mycobacterium tuberculosis.
    Howard NI; Dias MV; Peyrot F; Chen L; Schmidt MF; Blundell TL; Abell C
    ChemMedChem; 2015 Jan; 10(1):116-33. PubMed ID: 25234229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into substrate binding and catalysis in bacterial type I dehydroquinase.
    Maneiro M; Peón A; Lence E; Otero JM; Van Raaij MJ; Thompson P; Hawkins AR; González-Bello C
    Biochem J; 2014 Sep; 462(3):415-24. PubMed ID: 24957267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structures of Helicobacter pylori type II dehydroquinase inhibitor complexes: new directions for inhibitor design.
    Robinson DA; Stewart KA; Price NC; Chalk PA; Coggins JR; Lapthorn AJ
    J Med Chem; 2006 Feb; 49(4):1282-90. PubMed ID: 16480265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical Modification of a Dehydratase Enzyme Involved in Bacterial Virulence by an Ammonium Derivative: Evidence of its Active Site Covalent Adduct.
    González-Bello C; Tizón L; Lence E; Otero JM; van Raaij MJ; Martinez-Guitian M; Beceiro A; Thompson P; Hawkins AR
    J Am Chem Soc; 2015 Jul; 137(29):9333-43. PubMed ID: 26148116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-substituted-3-dehydroquinic acids as potent competitive inhibitors of type II dehydroquinase.
    Prazeres VF; Castedo L; Lamb H; Hawkins AR; González-Bello C
    ChemMedChem; 2009 Dec; 4(12):1980-4. PubMed ID: 19856378
    [No Abstract]   [Full Text] [Related]  

  • 13. Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy.
    Tran AT; West NP; Britton WJ; Payne RJ
    ChemMedChem; 2012 Jun; 7(6):1031-43. PubMed ID: 22461418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the water-binding pocket of the type II dehydroquinase enzyme in the structure-based design of inhibitors.
    Blanco B; Sedes A; Peón A; Otero JM; van Raaij MJ; Thompson P; Hawkins AR; González-Bello C
    J Med Chem; 2014 Apr; 57(8):3494-510. PubMed ID: 24689821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors.
    Tizón L; Otero JM; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Ainsa JA; Castedo L; González-Bello C
    J Med Chem; 2011 Sep; 54(17):6063-84. PubMed ID: 21780742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irreversible covalent modification of type I dehydroquinase with a stable Schiff base.
    Tizón L; Maneiro M; Peón A; Otero JM; Lence E; Poza S; van Raaij MJ; Thompson P; Hawkins AR; González-Bello C
    Org Biomol Chem; 2015 Jan; 13(3):706-16. PubMed ID: 25370445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic insight into the reaction catalysed by bacterial type II dehydroquinases.
    Coderch C; Lence E; Peón A; Lamb H; Hawkins AR; Gago F; González-Bello C
    Biochem J; 2014 Mar; 458(3):547-57. PubMed ID: 24392963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QM/MM simulations identify the determinants of catalytic activity differences between type II dehydroquinase enzymes.
    Lence E; van der Kamp MW; González-Bello C; Mulholland AJ
    Org Biomol Chem; 2018 Jun; 16(24):4443-4455. PubMed ID: 29767194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in type II dehydroquinase inhibitors: from concept to practice.
    González-Bello C; Castedo L
    Med Res Rev; 2007 Mar; 27(2):177-208. PubMed ID: 17004270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomolar inhibition of type II dehydroquinase based on the enolate reaction mechanism.
    Toscano MD; Payne RJ; Chiba A; Kerbarh O; Abell C
    ChemMedChem; 2007 Jan; 2(1):101-12. PubMed ID: 17068841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.